AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula **I**:



I

or a pharmaceutically acceptable salt or mixtures thereof,

wherein R^1 is selected from $-(L)_mR$, $-(L)_mAr^1$, or $-(L)_mCy^1$; L is an optionally substituted C_{1-6} alkylidene chain wherein up to two non-adjacent methylene units of L are optionally replaced by O, NR, NRCO, NRCS, NRCONR, NRCSNR, $NRCO_2$, CO, CO_2, CONR, CSNR, OC(O)NR, SO_2, SO_2NR, $NRSO_2$, $NRSO_2NR$, C(O)C(O), or $C(O)CH_2C(O)$; m is 0 or 1; Ar^1 is an optionally substituted aryl group selected from a 3-8 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and Cy^1 is an optionally substituted group selected from a 3-7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10-membered saturated or partially unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ar^1 and Cy^1 are each independently optionally substituted with y occurrences of $Z\text{-}R^Y$; wherein Z is a bond or is a C_1-C_6 alkylidene chain wherein up to two non-adjacent methylene units of Z are optionally replaced by CO, CO_2, COCO, CONR, CSNR, OCONR, NRNR, NRNRCO, NRCO, NRCS, $NRCO_2$, NRCONR, NRCSNR, SO, SO_2, $NRSO_2$, SO_2NR, $NRSO_2NR$, O, S, or NR; each occurrence of R^Y is independently selected from R', halogen, NO_2, CN, OR', SR', $N(R')_2$, NR'C(O)R', NR'C(S)R', $NR'C(O)N(R')_2$, $NR'C(S)N(R')_2$, $NR'CO_2R'$, C(O)R', CO_2R', OC(O)R', $C(O)N(R')_2$, $C(S)N(R')_2$, $OC(O)N(R')_2$, SOR', SO_2R', $SO_2N(R')_2$, $NR'SO_2R'$, $NR'SO_2N(R')_2$, C(O)C(O)R', or $C(O)CH_2C(O)R'$; and y is 0-5;

R^2 is selected from halogen, NO_2, -SR, $-N(R)_2$, $-(T)_nR$, or $-(T)_nAr^2$ wherein T is an optionally substituted C_{1-4} alkylidene chain wherein up to two non-adjacent methylene units of T are optionally replaced by O, NR, NRCO, NRCS, NRCONR, NRCSNR, $NRCO_2$, CO, CO_2, CONR, CSNR, OC(O)NR, SO_2, SO_2NR, $NRSO_2$, $NRSO_2NR$, C(O)C(O), or $C(O)CH_2C(O)$; n is 0 or 1; Ar^2 is an optionally substituted aryl group selected from a 5-6 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur wherein Ar^2 is independently optionally substituted with up to five substituents selected from $Q\text{-}R^X$; wherein Q is a bond or is a C_1-C_6 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO_2, COCO, CONR, CSNR, OCONR, NRNR, NRNRCO, NRCO, NRCS, $NRCO_2$, NRCONR, NRCSNR, SO, SO_2, $NRSO_2$, SO_2NR, $NRSO_2NR$, O, S, or NR; and each occurrence of R^X is independently selected from R', halogen, NO_2, CN, OR', SR', $N(R')_2$, NR'C(O)R', NR'C(S)R', $NR'C(O)N(R')_2$, $NR'C(S)N(R')_2$, $NR'CO_2R'$, C(O)R', CO_2R', OC(O)R', $C(O)N(R')_2$, $C(S)N(R')_2$, $OC(O)N(R')_2$, SOR', SO_2R', $SO_2N(R')_2$, $NR'SO_2R'$, $NR'SO_2N(R')_2$, C(O)C(O)R', or $C(O)CH_2C(O)R'$;

R^3 is hydrogen or an optionally substituted C_{1-4} aliphatic group;

X is selected from a valence bond, O, S, or NR;

R^4 is selected from -R, $-U\text{-}Ar^3$, or $-(U)_jCy^3$; U is an optionally substituted C_{1-6} alkylidene chain wherein up to two non-adjacent methylene units of U are optionally replaced by O, NR, NRCO, NRCS, NRCONR, NRCSNR, $NRCO_2$, CO, CO_2, CONR, CSNR, OC(O)NR, SO_2, SO_2NR, $NRSO_2$, $NRSO_2NR$, C(O)C(O), or $C(O)CH_2C(O)$; j is 0 or 1; Ar^3 is an optionally substituted aryl group selected from a 3-8 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and Cy^3 is an optionally substituted group selected from a 3-7-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10-membered saturated or partially unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ar^3 and Cy^3 are each independently optionally substituted with up to five substituents selected from $Y\text{-}R^Z$; wherein Y is a bond or is a C_1-C_6 alkylidene chain wherein up to two non-adjacent

methylene units of Y are optionally replaced by CO, CO_2, COCO, CONR, CSNR, OCONR, NRNR, NRNRCO, NRCO, NRCS, $NRCO_2$, NRCONR, NRCSNR, SO, SO_2, $NRSO_2$, SO_2NR, $NRSO_2NR$, O, S, or NR; and each occurrence of R^Z is independently selected from R', halogen, NO_2, CN, OR', SR', $N(R')_2$, NR'C(O)R', NR'C(S)R', $NR'C(O)N(R')_2$, $NR'C(S)N(R')_2$, $NR'CO_2R'$, C(O)R', CO_2R', OC(O)R', $C(O)N(R')_2$, $C(S)N(R')_2$, $OC(O)N(R')_2$, SOR', SO_2R', $SO_2N(R')_2$, $NR'SO_2R'$, $NR'SO_2N(R')_2$, C(O)C(O)R', or $C(O)CH_2C(O)R'$; or

wherein R^4 and R, taken together with the nitrogen form an optionally substituted 5-8 membered heterocyclyl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each occurrence of R is independently selected from hydrogen or an optionally substituted C_{1-6} aliphatic group, or two R on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, C_{6-10} aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein two R on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur,

provided that:

a) when X is NR; R, R^3, and R^4 are each hydrogen; R^2 is $-(T)_nR$ wherein n is 0 and R is hydrogen; and R^1 is $-(L)_mAr^1$ wherein m is 0; then Ar^1 is not:

i) 4-Cl or 4-OMe phenyl; or

ii) 3-CF_3 phenyl;

d) when X is a valence bond; R^4 is hydrogen; R^3 is CH_3; R^2 is either chloro or hydrogen; and R^1 is $-(L)_mAr^1$ wherein m is 0, then Ar^1 is not 3-trifluoromethyl phenyl or 2-fluoro-5-trifluoromethyl phenyl;

f) when X is a valence bond; R^4 is methyl; R^2 is $-(T)_nR$ wherein n is 0 and R is hydrogen; R^3 is hydrogen; and R^1 is $-(L)_mAr^1$ wherein m is 0; then Ar^1 is not 4-tolyl;

g) 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[1,6-dihydro-3-methyl-7-(4-nitrophenoxy)-6-oxo-5H-pyrazolo[4,3-c]pyridazin-5-yl]phenyl]-butanamide is excluded.

2. (Previously presented) The compound according to claim 1, wherein R^1 is $-(L)_mAr^1$ and Ar^1 is selected from one of the following groups:



1-1,



1-2,



1-3,



1-4,



1-5,



1-6,



1-7,



1-8,



1-9,



1-10,



1-11,



1-12,



1-13,



1-14,



1-15,



1-16,



1-17,



1-18,



1-19,



1-20,



1-21,



1-22,



1-23,



1-24,



1-25,



1-26,



1-27,



1-28,



1-29,



1-30,



1-31,



1-32,



1-33,



1-34,



1-35, and



1-36 .

3. (Previously presented) The compound according to claim 2, wherein Ar^1 is selected from one of the following groups:



1-5,



1-6,



1-7,



1-8,









1-9, **1-10,** **1-11,** **1-12,**






1-13, **1-14,** **1-15,** and **1-16** .

4. (Previously presented) The compound according to claim 3, wherein Ar^1 is selected from one of the following groups:






1-5, **1-6,** **1-7,** and **1-8** .

5. (Original) The compound according to claim 2, wherein R^1 is $-(L)_m-Ar^1$, m is 1 and compounds have the formula **IA-3**:



IA-3 .

6. (Original) The compound according to claim 2, wherein Ar^1 is phenyl with 0-5 occurrences of ZR^Y and compounds have the formula **IA-1-5**:



IA-1-5 .

7. (Original) The compound according to claim 1, wherein R^1 is $-(L)_m-Cy^1$ and compounds have the formula **IA-2**:



IA-2 .

8. (Previously presented) The compound according to claim 7, wherein Cy^1 is selected from one of the following groups:



2-1,



2-2,



2-3,



2-4,



2-5,



2-6,



2-7,



2-8,



2-9,



2-10,



2-11,



2-12, and



2-13 .

9. (Original) The compound according to claim 2, wherein L is an optionally substituted C_{1-6} straight or branched alkylidene chain wherein one methylene unit of L is optionally replaced by O, NR, NRCO, NRCS, NRCONR, NRCSNR, $NRCO_2$, CO, CO_2, CONR, CSNR, OC(O)NR, SO_2, SO_2NR, $NRSO_2$, $NRSO_2NR$, C(O)C(O), or $C(O)CH_2C(O)$ and m is 1.

10. (Original) The compound according to claim 9, wherein L is an optionally substituted C_{1-6} straight or branched alkylidene chain wherein one methylene unit of L is optionally replaced by CO, CO_2, CONR, CSNR, SO_2NR, and m is 1.

11. (Original) The compound according to claim 1, wherein R^1 is $-(L)_mR$, L is an optionally substituted C_{1-6} straight or branched alkylidene chain wherein one methylene unit of L is optionally replaced by O, NR, NRCO, NRCS, NRCONR, NRCSNR, $NRCO_2$, CO, CO_2, CONR, CSNR, OC(O)NR, SO_2, SO_2NR, $NRSO_2$, $NRSO_2NR$, C(O)C(O), or $C(O)CH_2C(O)$, R is an optionally substituted C_{1-6} aliphatic group and m is 1.

12. (Original) The compound according to claim 1, wherein R^2 is selected from halogen, NO_2, CN, -SR, $-N(R)_2$, or $-(T)_nR$, wherein R is selected from hydrogen or an optionally substituted C_{1-6} aliphatic group, or two R on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

13. (Original) The compound according to claim 12, wherein R^2 is selected from $-N(R)_2$, or $-(T)_nR$, wherein n is 0, and R is selected from hydrogen or an optionally substituted C_{1-6} aliphatic group.

14. (Original) The compound according to claim 13, wherein R^2 is $-(T)_nR$, wherein n is 0, and R is selected from hydrogen, CH_3, or CF_3.

15. (Original) The compound according to claim 1, wherein R^2 is $-(T)_nR$, wherein n is 0, R is hydrogen, and compounds have the formula **IB**:

IB .

16. (Original) The compound according to claim 1, wherein R^3 is hydrogen, methyl, ethyl, propyl, or isopropyl.

17. (Original) The compound according to claim 16, wherein R^3 is hydrogen or methyl.

18. (Original) The compound according to claim 1, wherein R^3 is hydrogen and compounds have the formula **IC**:



IC .

19. (Original) The compound according to claim 1, wherein X is selected from a valence bond or NR.

20. (Original) The compound according to claim 19, wherein X is NR and R is hydrogen.

21. (Original) The compound according to claim 1, wherein X is NR, R is hydrogen, and compounds have the formula **ID**:



ID .

22. (Previously presented) The compound according to claim 1, wherein X is O and compounds have the formula **IE**:



IE .

23. (Previously presented) The compound according to claim 1, wherein X is S and compounds have the formula **IF**:



IF .

24. (Previously presented) The compound according to claim 1, wherein X is NR, R is hydrogen, R^4 is -U-Ar^3 and compounds have the formula **IG**:



IG .

25. (Previously presented) The compound according to claim 1, wherein R^4 is -U-Ar^3 and Ar^3 is selected from one of the following groups:



1-5-a,



1-6-a,



1-7-a,



1-8-a,



1-9-a,



1-10-a,



1-11-a,



1-12-a,



1-13-a,



1-14-a,



1-15-a,



1-16-a,



1-37, and



1-38.

26. (Previously presented) The compound according to claim 25, wherein Ar^3 is selected from one of the following groups:



1-5-a,



1-6-a,



1-7-a,



1-8-a,



1-9-a,



1-10-a,



1-11-a,



1-12-a,




1-37, and **1-38** .

27. (Previously presented) The compound according to claim 26, wherein Ar^3 is selected from one of the following groups:






1-5-a, **1-6-a,** **1-7-a,** **1-8-a,**




1-9-a, and **1-37** .

28. (Previously presented) The compound according to claim 1, wherein R^4 is -U-Ar^3 and compounds have one of the following formulas:





IE, **IF,** and **IG** .

29. (Original) The compound according to claim 1, wherein X is NR, R is hydrogen, R^4 is -$(U)_jCy^3$ and compounds have the formula **IG-1**:



IG-1 .

30. (Previously presented) The compound according to claim 29, wherein Cy^3 is selected from one of the following groups:



2-1,



2-2,



2-3,



2-4,



2-5,



2-6,



2-7,



2-8,



2-9,



2-10,



2-11,



2-12, and



2-13 .

31. (Original) The compound according to claim 1, wherein X is NR, R and R^4 are hydrogen, and compounds have the formula **IL**:



IL .

32. (Original) The compound according to claim 1, wherein X is a valence bond and compounds have the formula **IM**:



IM .

33. (Original) The compound according to claim 1, wherein R^4 is R and R is an optionally substituted C_{1-6} aliphatic group.

34. (Original) The compound according to claim 1, wherein y is 0-5, and Ar^1 and Cy^1 are independently substituted with 0-5 occurrences of ZR^Y.

35. (Original) The compound according to claim 1, wherein y is 0-5, and Ar^3 and Cy^3 are independently substituted with 0-5 occurrences of YR^Z.

36. (Original) The compound according to claim 1, wherein y is 0, and Ar^1 is unsubstituted.

37. (Original) The compound according to claim 1, wherein ZR^Y and YR^Z groups are each independently halogen, NO_2, CN, or an optionally substituted group selected from C_{1-4} aliphatic, aryl, aralkyl, $-N(R')_2$, $-CH_2N(R')_2$, -OR', $-CH_2OR'$, -SR', $-CH_2SR'$, -COOR', or $-S(O)_2N(R')_2$.

38. (Original) The compound of claim 30, wherein ZR^Y and YR^Z groups are each independently Cl, CF_3, NO_2, $-S(O)_2N(R')_2$ or an optionally substituted group selected from C_{1-4} alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.

39. (Previously presented) The compound according to claim 1, wherein R^1 is $-(L)_mAr^1$, m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y, and compounds have one of the following formulas **IIA** or **IIA-1**:



IIA and



IIA-1 .

40. (Previously presented) The compound according to claim 1, wherein R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, R^1 is $-(L)_mAr^1$, wherein m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-3 occurrences of ZR^Y, and compounds have one of the following formulas **IIB** or **IIB-1**:



IIB and



IIB-1 .

41. (Previously presented) The compound according to claim 1, wherein R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, R^3 is hydrogen, R^1 is $-(L)_mAr^1$ wherein m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y, and compounds have one of the following formulas **IIC** or **IIC-1**:



IIC and



IIC-1 .

42. (Previously presented) The compound according to claim 1, wherein R^3 is hydrogen, R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, X is NR, R^1 is $-(L)_mAr^1$

wherein m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y, and compounds have one of the following formulas **IID** or **IID-1**:



IID and



IID-1 .

43. (Previously presented) The compound according to claim 1, wherein R^3 is hydrogen, R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, R^1 is $-(L)_mAr^1$ wherein m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y, and compounds have one of the following formulas **IIE, IIE-1, IIF, IIF-1, IIG,** or **IIG-1**:



IIE,



IIE-1,



IIF,



IIF-1,



IIG, and



IIG-1.

44. (Previously presented) The compound according to claim 1, wherein R^3 is hydrogen, R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, X is NH, R^1 is $-(L)_mAr^1$ wherein m is 0 or 1, Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y, and compounds have one of the following formulas **IIIE, IIIE-1, IIIF, IIIF-1, IIIG, or IIIG-1**:



IIIE,



IIIE-1,



IIIF,



IIIF-1,



IIIG, and



IIIG-1.

45. (Previously presented) The compound according to claim 1, wherein R^3 and R^4 are hydrogen, wherein R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, X is NR, Ar^1 is optionally substituted phenyl, R^1 is $-(L)_mAr^1$, and compounds have one of the following formulas **IIH** or **IIH-1**:



IIH and



IIH-1 .

46. (Previously presented) The compound according to claim 1, wherein R^3 and R^4 are hydrogen, wherein R^2 is $-(T)_nR$, wherein n is 0 and R is hydrogen, X is a valence bond, Ar^1 is optionally substituted phenyl, R^1 is $-(L)_mAr^1$, and compounds have one of the following formulas **IIJ** or **IIJ-1**:



IIJ and



IIJ-1 .

47. (Original) The compound according to any one of claims 39-46, wherein Ar^1 is phenyl optionally substituted with 0-5 occurrences of ZR^Y or wherein Ar^1 is pyridyl optionally substituted with 0-3 occurrences of ZR^Y.

48. (Original) The compound according to claim 47, wherein m is 0 or m is 1 and L is CH_2; y is 0-3; and each occurrence of ZR^Y is independently halogen, NO_2, CN, or an optionally substituted group selected from C_{1-4} aliphatic, aryl, aralkyl, $-N(R')_2$, $-CH_2N(R')_2$, -OR', $-CH_2OR'$, -SR', $-CH_2SR'$, -COOR', or $-S(O)_2N(R')_2$.

49. (Original) The compound according to claim 48, wherein each occurrence of ZR^Y is independently Cl, CF_3, NO_2, $-S(O)_2N(R')_2$ or an optionally substituted group selected from C_{1-4} alkoxy, phenyl, phenyloxy, benzyl, or benzyloxy.

50. (Original) The compound according to any one of claims 24-28, wherein Ar^3 is phenyl or quinazolyl optionally substituted with 0-5 occurrences of YR^Z or wherein Ar^3 is pyridyl or pyrimidinyl optionally substituted with 0-3 occurrences of YR^Z.

51. (Previously presented) The compound according to claim 50, wherein U is CH_2; X is NH; m is 0 or 1 and L is CH_2; y is 0-3; and each occurrence of YR^Z are each independently halogen, NO_2, CN, or an optionally substituted group selected from C_{1-4} alkyl, aryl, aralkyl, $-N(R')_2$, $-CH_2N(R')_2$, -OR', $-CH_2OR'$, -SR', $-CH_2SR'$, -COOR', or $-S(O)_2N(R')_2$.

52. (Previously presented) The compound according to claim 1, selected from one of the following compounds:



I-1,



I-2,



I-3,



I-4,



I-5,



I-7,



I-8,



I-9,



I-10,



I-15,



I-16,



I-18,



I-19,



I-20,



I-21,



I-22,



I-25,



I-26,



I-27,



I-28,



I-29,



I-30,



I-32,



I-33, and



I-35.

53. (Original) A pharmaceutically acceptable composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvent, or vehicle.

54-63. (Canceled)